BridgeBio’s recently announced sale of an FDA Priority Review Voucher for $110 million reflects a robust secondary market for these regulatory fast passes. Prices for Priority Review Voucher (“PRVs”) reflect the high stakes involved in the timing of the FDA review of a new drug application (“NDA”) or biologic license application (“BLA”). While the purchase of a voucher can help a drug’s sponsor shorten the time to market, it can also put immediate cash in the hands of the voucher seller seeking to tide itself over, particularly during a period of flagging investor interest in the biopharma sector.
Robert is a corporate lawyer advising clients on transactional, corporate governance and disclosure matters. His practice is broad-based, with particular emphasis on the representation of public companies in the life sciences sector.
His transactional practice focuses on mergers and acquisitions and strategic alliances structured to advance innovative technologies.
Working with management teams and boards of directors, Robert also advises on corporate governance policies, as well as matters relating to activist defense.
Robert advises clients on public disclosures regarding a range of important corporate developments.